AstraZeneca Breaks With Targacept | Chemical & Engineering News
Volume 92 Issue 42 | p. 17 | Concentrates
Issue Date: October 20, 2014

AstraZeneca Breaks With Targacept

Department: Business
Keywords: pharmaceuticals, biotech, neuroscience

AstraZeneca is pulling the plug on its long-term relationship with Targacept. The companies first partnered in late 2005 to develop molecules that modulate neuronal nicotinic receptors, but over the years they expanded their pact to include other types of drug candidates, all of which have failed. AstraZeneca’s biggest commitment came in 2009, when it shelled out $200 million for the rights to TC-5214, a treatment for major depressive disorder. The big pharma firm handed TC-5214 back to Targacept in 2012 after a failed Phase III study.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment